Pancreatic Cancer News and Research

RSS

Pancreatic cancer is the fourth leading cause of all cancer deaths in the United States and the third leading cause of cancer deaths in individuals ages 40 to 60. Approximately 37,000 Americans are diagnosed with pancreatic cancer each year, and, each year, approximately the same number die from it. Often, pancreatic cancer is found too late for surgical intervention, and chemotherapy and radiation treatments have little effect.

New study identifies key pathway for delivering antisense cancer drugs

Antisense oligonucleotides (ASOs) have been proposed as a therapeutic approach to shut down the production of faulty proteins in a wide variety of diseases, including cancer.

11 Aug 2026

New drug delivers promising survival gains in pancreatic cancer

About 90% of people with pancreatic cancer have pancreatic ductal adenocarcinoma (PDAC), which is driven by an activating mutation in the KRAS gene.

9 Aug 2026

Tuft cell-like cancers exhibit unique biological characteristics across multiple organs

A growing body of evidence suggests that a rare epithelial cell type known as the tuft cell may play a far more significant role in cancer than previously recognized.

6 Aug 2026

New study explores cholesterol-driven survival mechanisms in pancreatic cancer

A University of Oklahoma researcher has received a five-year, $2 million grant from the National Cancer Institute to investigate how pancreatic cancer uses cholesterol to survive chemotherapy.

6 Aug 2026

Expanded DepMap reveals new cancer vulnerabilities through 3D tumor models

For nearly a decade, the Cancer Dependency Map, or DepMap, at the Broad Institute has helped scientists uncover new cancer dependencies - the genetic changes some cancers need to thrive that can potentially be targeted by new cancer drugs.

5 Aug 2026

Engineered probiotic bacteria boost immune attack against pancreatic cancer

Cancer immunotherapies have transformed treatment for many cancers, but pancreatic cancer remains especially difficult to treat. One major reason is that pancreatic tumors often create a "cold" tumor microenvironment, where the tumor prevents immune cells from mounting a strong attack.

24 Jul 2026

Red meat intake emerges as a potential pancreatic cancer risk factor

A systematic review and meta-analysis of 16 studies involving nearly 2 million participants found that higher red meat intake was associated with a modestly higher risk of pancreatic cancer. Processed meat intake showed no statistically significant association, although variation between studies means a small effect cannot be excluded.

22 Jul 2026

New strategy boosts immune attack against pancreatic cancer

Researchers from the University of Minnesota Medical School have identified why pancreatic cancer is difficult for the immune system to recognize and attack, paving the way for a new approach to improve immunotherapy.

20 Jul 2026

Exercise oncology could unlock new therapeutic pathways against cancer

Regular exercise is associated with improved outcomes for many patients with cancer, yet those with advanced disease may be unable to participate in exercise-based interventions.

20 Jul 2026

Experimental drug shows promise against NRAS-driven melanoma

A research team from Huntsman Cancer Institute at the University of Utah (the U) reports that a groundbreaking pathway-targeted therapy could be an effective treatment for certain melanoma patients and fill an unmet clinical need for patients with advanced disease.

16 Jul 2026

Blood-based gene tests show promise for pancreatic cancer screening

Researchers at Kanazawa University report the blood-based gene expression tests may enable early pancreatic cancer screening and improve long-term survival.

16 Jul 2026

Experimental KRAS vaccine safely generates durable immune response against pancreatic cancer

Researchers at the Johns Hopkins Kimmel Cancer Center and its Skip Viragh Center for Pancreatic Cancer report that an experimental vaccine targeting mutant KRAS, one of the most common genetic drivers of pancreatic cancer, was safe and generated durable immune responses aimed at preventing the cancer in people at high risk.

16 Jul 2026

Self-assembling antibody drugs successfully target multiple cancer receptors

Modern anticancer medications that combine tumor-fighting drugs with proteins that specifically target cancer cells are a relatively new class of drug, often given to patients for whom standard chemotherapy has not worked.

15 Jul 2026

Patient-derived organoids uncover new targets for chronic pancreatitis treatment

Around three million people worldwide struggle with chronic pancreatitis, a condition wherein the pancreas becomes inflamed, scarred, and painful.

14 Jul 2026

Stealth nanoparticles improve pancreatic cancer treatment with fewer side effects

Pancreatic cancer is considered one of the most lethal cancer because it is often diagnosed late and is difficult to treat.

14 Jul 2026

New study identifies potential compound for pancreatic cancer treatment

Announcing a new article publication in BIO Integration. Fat mass and obesity-associated protein (FTO), an epitranscriptomic regulator, has been implicated in cancer progression and immune regulation but the therapeutic relevance in pancreatic cancer is unclear.

7 Jul 2026

HonorHealth offers new drug that doubles pancreatic cancer survival

Under an FDA ruling that expands access to clinical trials, HonorHealth Research Institute is one of the first in the nation to offer a new drug, Daraxonrasib, that based on early data nearly doubles the average survival time of patients with pancreatic cancer.

7 Jul 2026

Microbiome science merges with oncology for better cancer treatments

Cancer remains notoriously difficult to treat, partly because tumors co‑opt their surrounding environment, including the resident microbiota, to evade immune surveillance and resist conventional therapies.

7 Jul 2026

Targeted therapy shows promise against KRAS-driven metastatic pancreatic cancer

An investigational targeted therapy designed to block one of the most common genetic drivers of pancreatic cancer has shown promising early results when combined with standard first-line chemotherapy, according to research presented today at the ESMO Gastrointestinal Cancers Congress 2026.

3 Jul 2026

Targeted therapy doubles progression-free survival in rare bile duct cancer

Results of the ongoing eNRGy trial, a single-arm, multicenter, global phase 2 clinical trial evaluating zenocutuzumab in solid tumors positive for Neuregulin 1 (NRG1) gene fusions, reported manageable side effects and clinically meaningful efficacy – including a near doubling of progression-free survival compared to expectations with standard of care – in previously treated patients with advanced NRG1-positive cholangiocarcinoma.

2 Jul 2026